查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1862631

子宮內膜癌治療市場依治療方法、藥物類別、治療線、給藥途徑及給藥環境分類－2025-2032年全球預測

Endometrial Cancer Treatment Market by Treatment Type, Drug Class, Line Of Therapy, Mode Of Administration, Administration Setting - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，子宮內膜癌治療市場將成長至 137.7 億美元，複合年成長率為 5.64%。

關鍵市場統計數據
基準年 2024 88.7億美元
預計年份：2025年 93.8億美元
預測年份 2032 137.7億美元
複合年成長率 (%) 5.64%

簡要概述近期臨床、診斷和護理服務的進展如何重塑當今子宮內膜癌的治療模式。

子宮內膜癌的治療正經歷快速的臨床和營運變革時期，這主要得益於分子生物學的突破、治療方法創新以及醫療服務模式的轉變。腫瘤譜分析和生物標記指導治療選擇的進步重塑了診斷路徑，使臨床醫生能夠擺脫對傳統組織學檢查的單一依賴，轉而採用精準醫療方法來指導全身治療方案的選擇。同時，免疫調節劑和標靶藥物的聯合治療為以往治療選擇有限的患者拓展了治療選擇，而微創手術技術和前哨淋巴結活體組織切片則降低了手術全期併發症，並縮短了患者的康復時間。

本文對模式轉移創新、生物標記主導策略以及醫療保健去中心化等正在重塑子宮內膜癌治療軌蹟的因素進行了分析概述。

子宮內膜癌的治療格局正在經歷變革，這主要得益於精準腫瘤學、免疫療法聯合治療、不斷改進的手術標準以及醫療服務分散化。分子分層提升了生物標記（例如錯配修復狀態和特定標靶突變）的重要性，這影響了臨床試驗的設計，並擴大了標靶治療的適用患者群體。同時，PD-1抑制劑和CTLA-4標靶治療策略的興起，以及它們通常與抗血管生成藥物和標靶治療藥物聯合使用，標誌著治療策略正朝著多藥聯合全身治療的方向發展，以期在更多患者中實現持久療效。

對2025年關稅主導的貿易措施如何影響供應鏈韌性、籌資策略以及治療和診斷管道的臨床連續性進行觀點評估

2025年美國關稅政策為子宮內膜癌治療生態系統帶來了複雜的阻力和適應性挑戰，影響了供應鏈、臨床運作和籌資策略。部分進口藥品成分、診斷劑和醫療設備關稅的提高，增加了部分醫療機構和供應商的直接採購成本。為因應這項挑戰，採購部門正在加快供應商多元化，探索替代採購方案，並加強與國內生產合作夥伴的協作，以降低關稅波動帶來的風險。同時，這些營運調整也在進行中，旨在維持臨床試驗的連續性，避免臨床實驗藥物供應中斷。

透過深度細分，將治療類型、藥物類別、治療線、給藥方式和醫療環境連結起來，從而指導研發和商業化選擇。

在子宮內膜癌治療領域，清晰的細分對於將臨床創新轉化為營運和商業優先事項至關重要。治療類型細分包括化療、聯合治療、荷爾蒙療法、免疫治療、放射治療、放射線治療和標靶治療，每種治療方式在研發、劑量和報銷方面都有其獨特的考量。依藥物類別細分可以進一步拓展這一觀點，區分抗血管生成藥物、化療藥物、荷爾蒙療法、化療和分子標靶藥物，並進一步細化細分，例如化療中的含鉑類藥物和紫杉烷類藥物、荷爾蒙療法中的Aromatase抑製劑和孕激素、免疫治療中的CTLA-4和PD-1抑製劑，以及分子標靶藥物中的mTORTOR抑製劑、PARP抑製劑和蛋白酪氨酸激酶抑製劑。治療線細分則將臨床治療順序（第一線、二線、三線、四線及後續治療）置於具體的脈絡中，並指導臨床試驗終點、對照組的選擇以及醫保報銷方案的製定。

區域性洞察解釋了法規結構、診斷基礎設施和報銷模式如何影響全球市場中獲得治療的機會。

區域趨勢對子宮內膜癌治療和診斷的可近性途徑、監管重點和普及率有顯著影響。在美洲，監管機構和支付方優先考慮衛生技術評估 (HTA) 和真實世界證據，同時許多醫療系統正在投資分子診斷能力和門診輸液中心，以改善可及性並減少住院治療。這些區域性優先事項促進了在診斷網路完善的地區快速採用生物標記驅動療法，但也凸顯了某些地區先進診斷可及性仍然不均衡的現狀。

從公司層級進行的策略觀察強調了投資組合多元化、夥伴關係模式和診斷整合是該領域的關鍵競爭優勢。

製藥、生物技術、診斷和醫療設備公司的企業策略正趨向於整合解決方案，將新型療法與伴隨診斷和患者支持項目相結合。主要企業致力於建立多元化的產品組合，力求在變革性免疫療法和標靶治療與成熟的治療方法（如荷爾蒙療法療法和細胞毒性療法）之間取得平衡；而小規模的專業公司則專注於獨特的作用機制和生物標記主導的適應症。夥伴關係和策略聯盟日益圍繞著聯合治療的共同開發、旨在加速監管證據提交的聯合設計試驗以及旨在擴大地域覆蓋範圍的許可協議。

為指導診斷技術改進、供應鏈多元化、臨床策略最佳化以及與支付方合作，確保醫療服務的可近性和影響力，提供切實可行的建議。

產業領導者應優先採取一系列協同行動，將臨床創新轉化為持久的患者獲益，同時管控營運和市場進入風險。首先，需要投資建立強大的分子診斷計畫和夥伴關係，以確保生物標記驅動療法能夠精準篩選出合適的患者。這包括提升病理診斷能力，並完善報銷機制，避免診斷瓶頸。其次，應制定臨床開發計劃，評估從第一線治療到後續治療的各種方案和聯合治療，並納入患者報告結局和真實世界證據，以加強與支付方的溝通，並最佳化指南制定。

對證據收集和三角驗證過程進行透明描述，整合臨床文獻、註冊登記資料、相關人員訪談和營運分析，以得出嚴謹的研究結果。

本分析所依據的研究結合了對監管指南、同行評審的臨床文獻、公共臨床試驗註冊庫的系統性回顧，以及對臨床醫生、支付方、診斷負責人和商業高管的專家訪談。二手資料提供了有關治療機制、近期核准和指南變更以及外科和門診護理進展的背景資訊。一手研究透過與在研究設計、檢查室營運、醫院採購和支付方決策方面經驗豐富的相關人員進行定性對話，驗證了戰略檢驗，從而實現了對臨床趨勢和營運實際情況的三角驗證。

整合臨床創新和營運要務的最終結論，為改善整個護理路徑中的患者預後提供連貫的視角。

總之，子宮內膜癌治療領域呈現出一種良性張力，一方面是快速的臨床創新，另一方面是將這些創新成果惠及患者所需的複雜運作。生物標記指導的選擇、免疫療法和標靶藥物聯合治療，以及手術和門診管理的改進，正在共同拓展治療選擇，同時也需要新的診斷、物流和支付方參與策略。同時，貿易政策的變化和區域基礎設施的差異等外部因素，要求製造商、醫療服務提供者和支付方做出務實的調整，以確保患者能夠獲得治療並持續參與臨床試驗。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • PD-1 和新型查核點標靶療法合併治療進行性子宮內膜癌
  • 透過整合分子譜和基因生物標記來建構個人化治療策略
  • 早期子宮內膜癌患者中微創機器人輔助子宮切除術的使用日益增多
  • 開發抑制PI3K/AKT/mTOR路徑的口服標靶治療用於治療復發性子宮內膜癌
  • 引入前哨淋巴結定位以減少子宮內膜癌分期手術併發症
  • 利用真實世界證據資料庫最佳化子宮內膜癌的治療流程和患者預後
  • 高風險子宮內膜癌試驗中新興的VEGF抑制劑和化療聯合策略
  • 擴大數位健康平台規模，用於遠端監測子宮內膜癌患者的生活品質和不利事件
  • 促進與放射治療技術進步的整合，例如用於治療局部子宮內膜癌的近距離放射
  • 致力於研究如何彌合服務不足的子宮內膜癌患者群體在獲得新型療法方面的差距

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 子宮內膜癌治療市場（依治療方法）

  • 化療
  • 聯合治療
  • 荷爾蒙療法
  • 免疫療法
  • 放射線治療
  • 外科手術
  • 標靶治療

9. 依藥物類別分類的子宮內膜癌治療市場

  • 抗血管新生療法
  • 化療藥物
    • 含鉑類藥物
    • 紫杉烷類
  • 荷爾蒙療法
    • Aromatase抑制劑
    • 黃體素
  • 免疫療法
    • CTLA-4抑制劑
    • PD-1抑制劑
  • 標靶治療
    • mTOR抑制劑
    • PARP抑制劑
    • 蛋白酪氨酸激酶抑制劑

第10章 子宮內膜癌治療市場（依治療線分類）

  • 主要治療
  • 四線治療及以後
  • 二級治療
  • 三級治療

第11章 依給藥途徑分類的子宮內膜癌治療市場

  • 靜脈注射
  • 口服

第12章 子宮內膜癌治療市場（依給藥途徑分類）

  • 門診治療
  • 住院設施
  • 醫院門診部

第13章 各地區子宮內膜癌治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 子宮內膜癌治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國子宮內膜癌治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Eisai Co., Ltd.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca PLC
    • Pfizer Inc.
    • Novartis AG
    • Johnson & Johnson
    • Eli Lilly and Company
Product Code: MRR-521BAA36EC26

The Endometrial Cancer Treatment Market is projected to grow by USD 13.77 billion at a CAGR of 5.64% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.87 billion
Estimated Year [2025] USD 9.38 billion
Forecast Year [2032] USD 13.77 billion
CAGR (%) 5.64%

A concise introduction that contextualizes recent clinical, diagnostic, and care delivery advancements reshaping endometrial cancer treatment paradigms today

Endometrial cancer care has experienced an accelerated period of clinical and operational change driven by molecular insights, therapeutic innovation, and shifts in care delivery. Advances in tumor profiling and biomarker-driven treatment selection have reframed diagnostic pathways, enabling clinicians to move beyond histology alone toward precision approaches that guide systemic therapy choices. At the same time, combination regimens that pair immune modulation with targeted agents have expanded therapeutic options for patients who previously had limited choices, while minimally invasive surgical techniques and sentinel node mapping have reduced perioperative morbidity and shortened recovery timelines.

Transitioning from discovery to adoption, stakeholders across clinical, regulatory, and payer communities are aligning around evidence frameworks that emphasize meaningful clinical benefit and real-world effectiveness. Consequently, health systems and providers are adapting workflows to integrate outpatient-friendly administration modes and patient-reported outcome monitoring. These changes demand coordinated shifts in clinical operations, diagnostics infrastructure, and commercial strategies to ensure that innovations translate into improved patient outcomes and sustainable care pathways.

An analytical overview of paradigm-shifting innovations, biomarker-driven strategies, and care decentralization that are redefining endometrial cancer treatment pathways

The landscape of endometrial cancer treatment is undergoing transformative shifts driven by precision oncology, immunotherapy combinations, evolving surgical standards, and the decentralization of care. Molecular stratification has elevated the role of biomarkers such as mismatch repair status and specific actionable mutations, which in turn has influenced clinical trial design and broadened the population eligible for targeted interventions. Concurrently, the rise of PD-1 inhibitors and CTLA-4-directed strategies, often combined with antiangiogenic or targeted agents, illustrates a shift toward multimodal systemic regimens that seek to convert durable responses in a greater proportion of patients.

In parallel, care delivery is moving toward more outpatient-friendly models supported by oral targeted therapies and improved supportive care that reduce hospital stays. Surgical practice continues to evolve with less invasive approaches and enhanced recovery protocols that preserve quality of life. These dynamics are reinforcing cross-disciplinary collaborations among medical oncology, gynecologic surgery, radiation oncology, and molecular pathology. As a result, stakeholders are increasingly focused on evidence generation around combinatorial approaches, sequencing strategies across first line and subsequent lines of therapy, and the value proposition of precision diagnostics to guide therapeutic selection.

A clear-eyed assessment of how tariff-driven trade measures in 2025 have reshaped supply chain resilience, procurement strategies, and clinical continuity across treatment and diagnostic channels

The implementation of United States tariffs in 2025 has introduced a complex set of headwinds and adaptive responses across the endometrial cancer treatment ecosystem, touching supply chains, clinical operations, and procurement strategies. Increased duties on specific imported pharmaceutical components, diagnostic reagents, and medical devices have elevated direct procurement costs for some institutions and suppliers. In turn, procurement teams have accelerated supplier diversification, sought alternative sourcing agreements, and engaged more deeply with domestic manufacturing partners to mitigate exposure to tariff volatility. These operational adjustments have unfolded alongside efforts to preserve continuity of clinical trials and avoid interruptions to investigational agent supply.

Moreover, the tariffs have intensified scrutiny over inventory management and contractual terms across distributor networks, prompting stakeholders to renegotiate long-term agreements and to consider hedging strategies for critical consumables. Regulatory interactions and customs clearance processes have required closer coordination between manufacturers and supply chain partners to reduce lead times. Importantly, clinicians and health system leaders have focused on maintaining patient access by prioritizing treatment pathways that leverage locally produced agents or oral formulations less vulnerable to cross-border logistics constraints. Collectively, these adaptations reflect the sector's pragmatic approach to preserving treatment continuity and clinical research momentum in the face of evolving trade policy.

Deep segmentation-focused insights that connect treatment types, drug classes, lines of therapy, administration modes, and care settings to inform development and commercialization choices

Segmentation clarity is critical to translating clinical innovation into operational and commercial priorities across endometrial cancer care. Treatment type segmentation encompasses chemotherapy, combination therapy, hormone therapy, immunotherapy, radiation therapy, surgery, and targeted therapy, each of which presents different development, administration, and reimbursement considerations. Drug class granularity extends this view by distinguishing antiangiogenic therapy, chemotherapeutic agents, hormonal therapy, immunotherapy, and targeted therapy, with further subcategorization that highlights platinum based agents and taxanes under chemotherapeutics, aromatase inhibitors and progestins under hormonal therapy, CTLA-4 inhibitors and PD-1 inhibitors under immunotherapy, and mTOR inhibitors, PARP inhibitors, and tyrosine kinase inhibitors under targeted therapy. Line of therapy segmentation captures the clinical sequencing context across first line, second line, third line, and fourth line and beyond, which dictates trial endpoints, comparator selection, and payer narratives.

Mode of administration, separated into intravenous and oral delivery, informs site-of-care planning, adherence strategies, and patient support services. Meanwhile, administration setting-ambulatory care, hospital inpatient, and hospital outpatient-shapes operational workflows, capital requirements, and the economics of care delivery. Integrating these segmentation lenses enables stakeholders to pinpoint evidence gaps, prioritize development portfolios for specific clinical contexts, and design commercial models that reflect how treatments are used across real-world practice settings.

Regionally nuanced intelligence that explains how regulatory frameworks, diagnostic infrastructure, and reimbursement models influence therapeutic access across global markets

Regional dynamics exert a strong influence on access pathways, regulatory priorities, and adoption rates for endometrial cancer therapeutics and diagnostics. In the Americas, regulatory authorities and payers emphasize health technology assessment and real-world evidence, while many systems invest in molecular diagnostic capacity and outpatient infusion centers to improve access and reduce hospitalization. These regional priorities have supported rapid uptake of biomarker-driven treatments in settings with established diagnostic networks, but they have also underscored disparities where access to advanced diagnostics remains uneven.

Across Europe, Middle East & Africa, variations in national reimbursement frameworks, diagnostic infrastructure, and clinical guideline harmonization drive differentiated adoption. Stakeholders in these markets have placed emphasis on cross-border clinical collaborations, centralized pathology review for trial enrollment, and capacity building for precision diagnostics. In the Asia-Pacific region, accelerated investment in domestic biopharmaceutical capabilities, public-private partnerships, and expanding clinical trial activity have supported faster localization of novel agents. However, differences in regulatory pathways, pricing policies, and reimbursement timelines require tailored market entry strategies and adaptive evidence-generation plans to secure sustainable access across distinct national environments.

Strategic company-level observations that highlight portfolio diversification, partnership models, and diagnostic integration as key competitive differentiators in the sector

Corporate strategies across pharmaceutical, biotechnology, diagnostic, and device companies are converging on integrated solutions that pair novel therapeutics with companion diagnostics and patient support programs. Leading organizations focus on building diversified portfolios that balance transformational immunotherapies and targeted agents with established modalities such as hormonal and cytotoxic therapies, while smaller specialized firms concentrate on niche mechanisms and biomarker-driven indications. Partnerships and strategic alliances increasingly center on co-development of combination regimens, jointly designed trials that accelerate regulatory evidence, and licensing agreements that extend geographic reach.

In addition, contract research organizations and diagnostic manufacturers have intensified collaboration with sponsors to streamline trial enrollment through centralized testing and harmonized biomarker panels. Commercial teams are also evolving their engagement models to emphasize value communication toward payers and integrated delivery networks, leveraging health economic modeling and real-world data to substantiate comparative benefit. Across the competitive landscape, agility in clinical development, capabilities in companion diagnostics, and a demonstrated ability to negotiate access agreements will continue to separate market leaders from followers.

Action-oriented recommendations that guide leaders to strengthen diagnostics, diversify supply chains, optimize clinical strategies, and align payer engagement to secure access and impact

Industry leaders should prioritize a coordinated set of actions to translate clinical innovation into durable patient impact while managing operational and market access risks. First, invest in robust molecular diagnostic programs and partnerships to ensure accurate patient selection for biomarker-driven therapies; this includes supporting pathology capacity building and reimbursement pathways to avoid diagnostic bottlenecks. Next, design clinical development plans that evaluate sequencing and combinations across first-line and later lines of therapy, while embedding patient-reported outcomes and real-world evidence collection to strengthen payer discussions and guideline positioning.

Operationally, diversify supply chains and cultivate regional manufacturing partnerships to reduce tariff and logistical exposure, and adopt inventory strategies that preserve trial continuity. Commercially, develop value communication strategies that stress clinical differentiation, health economic impact, and adherence support, particularly for oral therapies that shift care to ambulatory and outpatient settings. Finally, engage early with payers and regulatory authorities to co-create evidence frameworks that accelerate access decisions and to pursue adaptive reimbursement approaches tied to outcomes data. Implementing these steps will enhance organizational resilience and increase the probability that clinical advances yield meaningful benefits at scale.

A transparent description of the evidence gathering and triangulation process integrating clinical literature, registries, stakeholder interviews, and operational analysis to produce rigorous insights

The research underpinning this analysis combined a structured review of regulatory guidance, peer-reviewed clinical literature, public clinical trial registries, and expert interviews with clinicians, payers, diagnostics leaders, and commercial executives. Secondary sources provided context on therapeutic mechanisms, recent approvals and guideline changes, and advances in surgical and outpatient care. Primary research validated strategic hypotheses through qualitative dialogues with stakeholders experienced in trial design, laboratory operations, hospital procurement, and payer decision-making, enabling triangulation of clinical trends with operational realities.

Data synthesis employed a thematic approach to map clinical innovations against care delivery models and regional access constraints. Methodological rigor included cross-validation of clinical endpoints, therapy sequences, and diagnostic dependencies, as well as sensitivity to policy and tariff shifts that affect supply chains. Limitations of the methodology include reliance on available public clinical data and stakeholder perspectives at a particular point in time; consequently, the analysis emphasizes evidence-based insights and actionable implications rather than speculative projections.

A definitive conclusion that synthesizes clinical innovations and operational imperatives into a coherent outlook for delivering improved patient outcomes across care pathways

In conclusion, the treatment landscape for endometrial cancer is characterized by a productive tension between rapid clinical innovation and the operational complexities required to deliver those advances to patients. Biomarker-driven selection, immunotherapy and targeted agent combinations, and improvements in surgical and outpatient management are converging to broaden therapeutic possibilities and to demand new diagnostic, logistical, and payer-aligned strategies. At the same time, external factors such as trade policy shifts and regional infrastructure variability require pragmatic adaptations by manufacturers, providers, and payers to safeguard access and clinical trial continuity.

Looking forward, success will accrue to organizations that integrate robust diagnostic capabilities, pursue rational combination and sequencing trials, and align commercial models with evolving care settings. By balancing scientific ambition with operational resilience and payer collaboration, stakeholders can convert promising clinical innovations into measurable improvements in patient outcomes and system sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of immunotherapy combinations targeting PD-1 and novel checkpoints in advanced endometrial cancer
  • 5.2. Integration of molecular profiling and genomic biomarkers for personalized endometrial cancer treatment strategies
  • 5.3. Increased adoption of minimally invasive robotic-assisted hysterectomy for early-stage endometrial cancer patients
  • 5.4. Development of oral targeted therapies inhibiting PI3K/AKT/mTOR pathway in recurrent endometrial carcinoma management
  • 5.5. Implementation of sentinel lymph node mapping to reduce surgical morbidity in endometrial cancer staging
  • 5.6. Utilization of real-world evidence databases to optimize treatment algorithms and patient outcomes in endometrial cancer
  • 5.7. Emergence of combination strategies pairing VEGF inhibitors with chemotherapy in high-risk endometrial cancer trials
  • 5.8. Growth of digital health platforms for remote monitoring of quality of life and adverse events in endometrial cancer patients
  • 5.9. Advances in radiotherapy techniques such as brachytherapy boost integration for localized endometrial carcinoma
  • 5.10. Focus on disparities research addressing access to novel therapeutics in underserved endometrial cancer populations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endometrial Cancer Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
  • 8.2. Combination Therapy
  • 8.3. Hormone Therapy
  • 8.4. Immunotherapy
  • 8.5. Radiation Therapy
  • 8.6. Surgery
  • 8.7. Targeted Therapy

9. Endometrial Cancer Treatment Market, by Drug Class

  • 9.1. Antiangiogenic Therapy
  • 9.2. Chemotherapeutic Agents
    • 9.2.1. Platinum Based Agents
    • 9.2.2. Taxanes
  • 9.3. Hormonal Therapy
    • 9.3.1. Aromatase Inhibitors
    • 9.3.2. Progestins
  • 9.4. Immunotherapy
    • 9.4.1. CTLA-4 Inhibitors
    • 9.4.2. PD-1 Inhibitors
  • 9.5. Targeted Therapy
    • 9.5.1. MTOR Inhibitors
    • 9.5.2. PARP Inhibitors
    • 9.5.3. Tyrosine Kinase Inhibitors

10. Endometrial Cancer Treatment Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Fourth Line And Beyond
  • 10.3. Second Line
  • 10.4. Third Line

11. Endometrial Cancer Treatment Market, by Mode Of Administration

  • 11.1. Intravenous
  • 11.2. Oral

12. Endometrial Cancer Treatment Market, by Administration Setting

  • 12.1. Ambulatory Care
  • 12.2. Hospital Inpatient
  • 12.3. Hospital Outpatient

13. Endometrial Cancer Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Endometrial Cancer Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Endometrial Cancer Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck & Co., Inc.
    • 16.3.2. GlaxoSmithKline plc
    • 16.3.3. Eisai Co., Ltd.
    • 16.3.4. Bristol-Myers Squibb Company
    • 16.3.5. F. Hoffmann-La Roche Ltd
    • 16.3.6. AstraZeneca PLC
    • 16.3.7. Pfizer Inc.
    • 16.3.8. Novartis AG
    • 16.3.9. Johnson & Johnson
    • 16.3.10. Eli Lilly and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ENDOMETRIAL CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)

TABLE